Axsome Therapeutics, Inc. (AXSM) — Institutional Holders, Q2 2026 (page 6)

508 institutional investment managers reported a AXSM position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $9.3B. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 501 to 508. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

AXSM 13F holders ranked 501–508 of 508

Institutional investors reporting a position in Axsome Therapeutics, Inc. on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
Rialto Wealth Management#501 · 2 sh$490.00New
SouthState Bank#502 · 2 sh$490.00New
Manchester Capital Management#503 · 1 sh$245.00New
GHP Investment Advisors#504 · 1 sh$245.000.0%
Concord Wealth Partners#505 · 1 sh$245.00New
TFC Financial Management#506 · 1 sh$245.000.0%
NOMURA ASSET MANAGEMENT LTD#507 · 0 sh$0.00New
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#508 · 45,663 sh—+11.0%

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.